Table 1. Correlation between the expression of stathmin1 and clinical classification in gastric cancer.
|
Immunoreactivity case No. (%)
|
||||
|---|---|---|---|---|
| Clinical classification | Total | Negative | Positive | P-value* |
| Age at surgery (years) | 0.202 | |||
| <60 | 120 | 60 (50.0) | 60 (50.0) | |
| 60⩽, <70 | 68 | 25 (36.7) | 43 (63.3) | |
| 70⩽ | 38 | 16 (42.1) | 22 (57.9) | |
| Gender (diffuse type) | 0.628 | |||
| Male | 43 | 31 (72.1) | 12 (27.9) | |
| Female | 51 | 39 (76.5) | 12 (23.5) | |
| Gender (intestinal type) | 0.464 | |||
| Male | 105 | 24 (22.9) | 81 (77.1) | |
| Female | 27 | 8 (29.6) | 19 (70.4) | |
| N stages (diffuse type) | 0.008 | |||
| N0∼N1 | 70 | 57 (81.4) | 13 (18.6) | |
| N2–N3 | 24 | 13 (54.2) | 11 (45.8) | |
| N stages (intestinal type) | 1.000 | |||
| N0∼N1 | 116 | 27 (23.3) | 89 (76.7) | |
| N2–N3 | 16 | 4 (25.0) | 12 (75.0) | |
| TNM stage (diffuse type) | 0.005 | |||
| 1∼2 | 58 | 49 (84.5) | 9 (15.5) | |
| 3∼4 | 36 | 21 (58.3) | 15 (41.7) | |
| TNM stage (intestinal type) | 0.946 | |||
| 1∼2 | 107 | 25 (23.4) | 82 (76.6) | |
| 3∼4 | 25 | 6 (24.0) | 19 (76.0) | |
| Vascular invasion (diffuse type) | 0.006 | |||
| Negative | 61 | 51 (83.6) | 10 (16.4) | |
| Positive | 33 | 19 (57.6) | 14 (42.4) | |
| Vascular invasion (intestinal type) | 0.634 | |||
| Negative | 98 | 22 (22.4) | 76 (77.6) | |
| Positive | 34 | 9 (26.5) | 25 (73.5) | |
Abbreviation: TNM=The tumour-node-metastasis staging system. *P<0.05 was defined as significant, Fisher's exact test.